New antibiotic and method for developing it exploits microbes' natural environment
the ONA take:
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method. Teixobactin was tested in mice and easily cured severe infections, with no side effects.
Testing in humans will not begin for approximately 2 years, according to the researchers; therefore, its safety and effectiveness are not known at this time.
Even if the drug passes all the tests, it may not be available for 5 or 6 years. Importantly, the researchers are excited about the method used to produce this antibiotic because it has the potential to lead to the discovery of more natural compounds to fight infections and cancer.
In this method, drugs are extracted from bacteria that live in dirt. The method exploits the biological antibiotics found in the natural environment—the dirt—where microbes exist.
The process involves diluting a soil sample and placing it on a specialized device. The device is then placed into a box full of the same soil the sample came from, thereby tricking the bacteria into growing into a colony in its natural environment. The method may help resolve two significant issues in global health: the increase in infections that resist commonly used drugs and the lack of new antibiotics to replace those that are no longer effective.
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|